Tegsedi (Inotersen Sodium) Patent Expiration, LOE Window & CMS Spending

Tegsedi (Inotersen Sodium) by Akcea Therapeut: FDA Orange Book core substance LOE 2031-04-29, 0 AB generics, $1.3M 2024 CMS Part D & Medicaid spend.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAkcea Therapeut
FDA Application & PathwayN211172 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2031-04-29
Last Listed Patent or Exclusivity Date2031-04-29
Orange Book Patents (*PED Extensions)3 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$1.3M
2024 Medicare Part D Spend$1.3M
2024 Medicaid Spend$0
Reported Wholesale Price Change (CA SB 17)0 statutory filings in 2023 to 2026 panel